Heterocyclic Building Blocks-piperidine

On February 8, 2007, Williams, Theresa M. published a patent.Recommanded Product: Benzyl 7′-chloro-2′-oxo-1′,2′-dihydrospiro[piperidine-4,4′-pyrido[2,3-d][1,3]oxazine]-1-carboxylate The title of the patent was Preparation of heterocyclic benzodiazepine derivatives as CGRP receptor antagonists. And the patent contained the following:

The title compounds with general formula I [wherein R2 = independently H, alkyl, cycloalkyl, aryl, heteroaryl, etc.; R7 = (un)substituted alkyl, alkenyl, alkynyl cycloalkyl, etc; D = N or C(R1), where R1 = independently (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, etc.; W = O, (un)substituted NH, or (un)substituted CH2; X = C or S; Y = O, N(CN), NC(=O)NH2, etc.; and Z = (un)substituted piperidinyl, aryl, or arylamino] or pharmaceutically acceptable salts and diastereomers thereof were prepared as antagonists of calcitonin gene-related peptide (CGRP) receptors for the treatment or prevention of diseases in which the CGRP is involved, such as migraine. For example, compound II was prepared in a multi-step synthesis. I showed antagonistic activity against CGRP receptor with IC50 values of about 50 μM in native receptor binding assay, native receptor functional assay, etc. The experimental process involved the reaction of Benzyl 7′-chloro-2′-oxo-1′,2′-dihydrospiro[piperidine-4,4′-pyrido[2,3-d][1,3]oxazine]-1-carboxylate(cas: 883984-95-0).Recommanded Product: Benzyl 7′-chloro-2′-oxo-1′,2′-dihydrospiro[piperidine-4,4′-pyrido[2,3-d][1,3]oxazine]-1-carboxylate

The Article related to preparation benzodiazepine piperidine benzene, cgrp receptor antagonist treatment human headache migraine, Heterocyclic Compounds (More Than One Hetero Atom): Diazepines and other aspects.Recommanded Product: Benzyl 7′-chloro-2′-oxo-1′,2′-dihydrospiro[piperidine-4,4′-pyrido[2,3-d][1,3]oxazine]-1-carboxylate

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem

Sriramudu, B.; Satyanarayana, B.; Rao, S. Venkat; Krishna, N.; Murali, Krishna P.; Ramachandran, D. published an article in 2018, the title of the article was Synthesis and characterization of biological active compounds contain benzimidazole piperidine analogues.Recommanded Product: 4-(4-Chlorophenyl)piperidin-4-ol And the article contains the following content:

A series of compounds namely, 1-(3-(piperidin-1-yl)propyl)-1H-benzo[d]imidazol-2(3H)-ones were synthesized from 1-(3-chloropropyl)-1H-benzo[d]imidazol-2(3H)-one and 4-substituted piperidines by using preamble chem. reactions, which exhibited good antibacterial and antifungal activities. They were structurally related to Domperidone, these results could help full for deriving more potential drug mols. The experimental process involved the reaction of 4-(4-Chlorophenyl)piperidin-4-ol(cas: 39512-49-7).Recommanded Product: 4-(4-Chlorophenyl)piperidin-4-ol

The Article related to chloropropyl benzimidazolone piperidine alkylation, piperidylpropyl benzimidazolone preparation antibacterial antifungal activity, Heterocyclic Compounds (More Than One Hetero Atom): Imidazoles and other aspects.Recommanded Product: 4-(4-Chlorophenyl)piperidin-4-ol

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem

On March 13, 2013, Bao, Xiaofeng; Liu, Duliang published an article.COA of Formula: C11H14ClNO The title of the article was Radiosynthesis of 18F-labeled N-desmethyl-loperamide analogues for prospective molecular imaging radiotracers. And the article contained the following:

A simple procedure for preparing fluoroethyl-N-desmethyl-loperamide and its analog I [X = (CH2)2, (CH2)3, Y = F] was developed. Standard compound I [X = (CH2)2, Y = F] was synthesized in useful yields for radiolabeling anal. [N-Ethyl-18F]N-desmethyl-loperamide, I [X = (CH2)2, Y = 18F], was rapidly and efficiently labeled with no-carrier added fluorine-18 (t1/2 = 109.7 min) by treatment of readily prepared [18F]1-bromo-2-fluoroethane with a N-desmethyl-loperamide precursor at a consistent 7% radiochem. yield. This procedure was also adapted to the radiosynthesis of I [X = (CH2)2, Y = 18F] by [18F]ethylene tosylate, but at a lower 3% radiochem. yield. The experimental process involved the reaction of 4-(4-Chlorophenyl)piperidin-4-ol(cas: 39512-49-7).COA of Formula: C11H14ClNO

The Article related to loperamide analog radiosynthesis loperamide fluorine 18 pet permeability glycoprotein, Heterocyclic Compounds (One Hetero Atom): Other 6-Membered Rings and other aspects.COA of Formula: C11H14ClNO

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem

On June 30, 1990, Nemeryuk, M. P.; Sedov, A. L.; Ryabokon, N. A.; Ershova, Yu. A.; Sokolova, A. S.; Losev, A. G.; Chernov, V. A.; Safonova, T. S. published an article.Application In Synthesis of 4-Chloro-6-(piperidin-1-yl)pyrimidin-5-amine The title of the article was 4(5)-Substituted 1,2,3-triazole-5(4)-carboxylic acid derivatives: synthesis and antitumor activity. And the article contained the following:

The title compounds [I, X = e.g., CO2Me, C(:NH)SMe, piperidino- or morpholino(imino)methyl, and Y = SMe, Cl, CN, OMe, SCH2Ph, 1-methyl-1-isobutyl-4-nitroimidazolyl-5-thio) were prepared by the diazotization of aminopyrimidines. The structure of the products was dependent on the type of substituents present and the conditions of carrying out the reaction. The compounds had antitumor activity both in vitro and in vivo. The highest activity was shown by I (X = CO2Me, Y = 2-nitro-5-acetyl-3-thienylthio) or X = C(:NH)NMe2 and Y = OMe). I had low toxicity. The experimental process involved the reaction of 4-Chloro-6-(piperidin-1-yl)pyrimidin-5-amine(cas: 84762-70-9).Application In Synthesis of 4-Chloro-6-(piperidin-1-yl)pyrimidin-5-amine

The Article related to triazolecarboxylate derivative preparation antitumor, Pharmacology: Effects Of Neoplasm Inhibitors and Cytotoxic Agents and other aspects.Application In Synthesis of 4-Chloro-6-(piperidin-1-yl)pyrimidin-5-amine

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem

On August 13, 2020, Robles, Omar; Jackson, Jeffrey J.; Marshall, Lisa; Talay, Oezcan; Chian, David; Cutler, Gene; Diokno, Raymond; Hu, Dennis X.; Jacobson, Scott; Karbarz, Emily; Kassner, Paul D.; Ketcham, John M.; McKinnell, Jenny; Meleza, Cesar; Reilly, Maureen K.; Riegler, Erin; Shunatona, Hunter P.; Wadsworth, Angela; Younai, Ashkaan; Brockstedt, Dirk G.; Wustrow, David J.; Zibinsky, Mikhail published an article.Application In Synthesis of tert-Butyl 3-(piperidin-4-yl)azetidine-1-carboxylate The title of the article was Novel Piperidinyl-Azetidines as Potent and Selective CCR4 Antagonists Elicit Antitumor Response as a Single Agent and in Combination with Checkpoint Inhibitors. And the article contained the following:

The C-C chemokine receptor 4 (CCR4) is broadly expressed on regulatory T cells (Treg) as well as other circulating and tissue-resident T cells. Treg can be recruited to the tumor microenvironment (TME) through the C-C chemokines CCL17 and CCL22. Treg accumulation in the TME has been shown to dampen the antitumor immune response and is thought to be an important driver in tumor immune evasion. Preclin. and clin. data suggest that reducing the Treg population in the TME can potentiate the antitumor immune response of checkpoint inhibitors. We have developed small-mol. antagonists of CCR4, featuring a novel piperidinyl-azetidine motif, that inhibit the recruitment of Treg into the TME and elicit antitumor responses as a single agent or in combination with an immune checkpoint blockade. The discovery of these potent, selective, and orally bioavailable CCR4 antagonists(I), and their activity in in vitro and in vivo models, is described herein. The experimental process involved the reaction of tert-Butyl 3-(piperidin-4-yl)azetidine-1-carboxylate(cas: 1251006-64-0).Application In Synthesis of tert-Butyl 3-(piperidin-4-yl)azetidine-1-carboxylate

The Article related to antitumor ccr4 antagonists checkpoint inhibitors combination immune response bioavailability, Pharmacology: Effects Of Neoplasm Inhibitors and Cytotoxic Agents and other aspects.Application In Synthesis of tert-Butyl 3-(piperidin-4-yl)azetidine-1-carboxylate

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem

On September 23, 2021, Barbaraci, Carla; Giurdanella, Giovanni; Leotta, Claudia Giovanna; Longo, Anna; Amata, Emanuele; Dichiara, Maria; Pasquinucci, Lorella; Turnaturi, Rita; Prezzavento, Orazio; Cacciatore, Ivana; Zuccarello, Elisa; Lupo, Gabriella; Pitari, Giovanni Mario; Anfuso, Carmelina Daniela; Marrazzo, Agostino published an article.Synthetic Route of 39512-49-7 The title of the article was Haloperidol Metabolite II Valproate Ester (S)-(-)-MRJF22: Preliminary Studies as a Potential Multifunctional Agent Against Uveal Melanoma. And the article contained the following:

Increased angiogenesis and vascular endothelial growth factor (VEGF) levels contribute to higher metastasis and mortality in uveal melanoma (UM), an aggressive malignancy of the eye in adults. (±)-MRJF22, a prodrug of the sigma (σ) ligand haloperidol metabolite II conjugated with the histone deacetylase (HDAC) inhibitor valproic acid, has previously demonstrated a promising antiangiogenic activity. Herein, the asym. synthesis of (R)-(+)-MRJF22 and (S)-(-)-MRJF22 was performed to investigate their contribution to (±)-MRJF22 antiangiogenic effects in human retinal endothelial cells (HREC) and to assess their therapeutic potential in primary human uveal melanoma (UM) 92-1 cell line. While both enantiomers displayed almost identical capabilities to reduce cell viability than the racemic mixture, (S)-(-)-MRJF22 exhibited the highest antimigratory effects in endothelial and tumor cells. Given the fundamental contribution of cell motility to cancer progression, (S)-(-)-MRJF22 (I) may represent a promising candidate for novel antimetastatic therapy in patients with UM. The experimental process involved the reaction of 4-(4-Chlorophenyl)piperidin-4-ol(cas: 39512-49-7).Synthetic Route of 39512-49-7

The Article related to melanoma antimetastatic therapy vegf enantiomers antiangiogenic antiproliferative valproate ester, Pharmacology: Effects Of Neoplasm Inhibitors and Cytotoxic Agents and other aspects.Synthetic Route of 39512-49-7

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem

On August 25, 2016, Damont, Annelaure; Goutal, Sebastien; Auvity, Sylvain; Valette, Heric; Kuhnast, Bertrand; Saba, Wadad; Tournier, Nicolas published an article.Reference of 4-(4-Chlorophenyl)piperidin-4-ol The title of the article was Imaging the impact of cyclosporin A and dipyridamole on P-glycoprotein (ABCB1) function at the blood-brain barrier: A [11C]-N-desmethyl-loperamide PET study in nonhuman primates. And the article contained the following:

Cyclosporin A (CsA) and dipyridamole (DPy) are potent inhibitors of the P-glycoprotein (P-gp; ABCB1) in vitro. Their efficacy at inhibiting P-gp at the blood-brain barrier (BBB) is difficult to predict. Efficient and readily available (i.e. marketed) P-gp inhibitors are needed as probes to investigate the role of P-gp at the human BBB. In this study, the P-gp inhibition potency at the BBB of therapeutic doses of CsA or DPy was evaluated in baboons using Positron Emission Tomog. (PET) imaging with [11C]-N-desmethyl-loperamide ([11C]dLop), a radiolabeled P-gp substrate. The preparation of dLop as authentic standard and [11C]dLop as radiotracer were revisited so as to improve their production yields. [11C]dLop PET imaging was performed in the absence (n = 3, baseline condition) and the presence of CsA (15 mg/kg/h i.v., n = 3). Three animals were injected with i.v. DPy at either 0.56 or 0.96 or 2 mg/kg (n = 1), corresponding to the usual, maximal and twice the maximal dose in patients, resp., administered immediately before PET. [11C]dLop brain kinetics as well as [11C]dLop kinetics and radiometabolites in arterial plasma were measured to calculate [11C]dLop area-under the time-activity curve from 10 to 30 min in the brain (AUCbrain) and in plasma (AUCplasma). [11C]dLop brain uptake was described by AUCR = AUCbrain/AUCplasma. CsA as well as DPy did not measurably influence [11C]dLop plasma kinetics and metabolism Baseline AUCR (0.85 ± 0.29) was significantly enhanced in the presence of CsA (AUCR = 10.8 ± 3.6). Injection of pharmacol. dose of DPy did not enhance [11C]dLop brain distribution with AUCR being 1.2, 0.9 and 1.1 after administration of 0.56, 0.96 and 2 mg/kg DPy doses, resp. We used [11C]dLop PET imaging in baboons, a relevant in vivo model of P-gp function at the BBB, to show the P-gp inhibition potency of therapeutic dose CsA. Despite in vitro P-gp inhibition potency, usual doses DPy are not likely to inhibit P-gp function at the BBB. The experimental process involved the reaction of 4-(4-Chlorophenyl)piperidin-4-ol(cas: 39512-49-7).Reference of 4-(4-Chlorophenyl)piperidin-4-ol

The Article related to cyclosporin a dipyridamole pgp inhibitor abcb1 drug interaction, bbb, drug-drug interaction, positron emission tomography, radiochemistry, stress-test, Pharmacology: Effects Of Inflammation Inhibitors and Immune Agents and other aspects.Reference of 4-(4-Chlorophenyl)piperidin-4-ol

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem

On July 28, 2020, Crew, Andrew P.; Hornberger, Keith R.; Wang, Jing; Dong, Hanqing; Qian, Yimin; Crews, Craig M.; Jaime-Figueroa, Saul published a patent.COA of Formula: C13H24N2O2 The title of the patent was Preparation of heterocyclic compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides. And the patent contained the following:

The disclosure relates to bifunctional compounds of formula I, which find utility as modulators of rapidly accelerated fibrosarcoma (RAF, such as c-RAF, A-RAF and/or B-RAF, the target protein). In particular, the present disclosure is directed to bifunctional compounds I, wherein ULM is a small mol. E3 ubiquitin ligand binding moiety that binds to E3 ubiquitin ligase selected from a group consisting of Von Hippel-Lindau, inhibitors of apoptosis proteins or mouse double-minute homolog 2 ligand; PTM is a small mol. that binds the target protein RAF; L is a bond and a chem. linking moiety; and their pharmaceutically acceptable salts, enantiomers, stereoisomers, solvates, polymorphs and prodrugs thereof, are claimed. Thus, compound II was prepared by a multistep procedure (procedure given). The invention compounds were evaluated for their B-RAF degradation activity. From the assay, it was determined that compound II exhibited DC50 value in the range of < 100 nM to > 50 nM and Dmax value of > 70%. The experimental process involved the reaction of tert-Butyl 3-(piperidin-4-yl)azetidine-1-carboxylate(cas: 1251006-64-0).COA of Formula: C13H24N2O2

The Article related to dipeptide preparation apoptosis fibrosarcoma polypeptide modulator ubiquitin ligase, heterocycle preparation braf protein target degradation, Amino Acids, Peptides, and Proteins: Poly(Amino Acids) and Peptides and other aspects.COA of Formula: C13H24N2O2

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem

On November 24, 2021, Dorsheimer, Julia R.; Ashley, Melissa A.; Rovis, Tomislav published an article.Synthetic Route of 362703-57-9 The title of the article was Dual Nickel/Photoredox-Catalyzed Deaminative Cross-Coupling of Sterically Hindered Primary Amines. And the article contained the following:

Authors report a method to activate α-3° amines for deaminative arylation via condensation with an electron-rich aldehyde and merge this reactivity with nickel metallaphotoredox to generate benzylic quaternary centers, a common motif in pharmaceuticals and natural products. The reaction is accelerated by added ammonium salts. Evidence is provided in support of two roles for the additive – inhibition of nickel black formation and acceleration of the overall reaction rate. Authors demonstrate a robust scope of amine and haloarene coupling partners and show an expedited synthesis of ALK2 inhibitors. The experimental process involved the reaction of tert-Butyl 4-amino-4-(2-methoxy-2-oxoethyl)piperidine-1-carboxylate(cas: 362703-57-9).Synthetic Route of 362703-57-9

The Article related to primary amine deaminative cross coupling nickel photoredox, Benzene, Its Derivatives, and Condensed Benzenoid Compounds: General and other aspects.Synthetic Route of 362703-57-9

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem

On September 10, 2015, Takayama, Tetsuo; Shibata, Tsuyoshi; Shiozawa, Fumiyasu; Kawabe, Kenichi; Shimizu, Yuki; Hamada, Makoto; Hiradate, Akira; Takahashi, Masato; Ushiyama, Fumihito; Oi, Takahiro; Shirasaki, Yoshihisa; Matsuda, Daisuke; Koizumi, Chie; Kato, Sota published a patent.Synthetic Route of 362703-57-9 The title of the patent was Pharmaceutical compositions containing N-[[1-[[6-(4-chlorophenoxy)-3-pyridinyl]methyl]-4-hydroxy-2-oxo-1,2,5,6-tetrahydro-3-pyridinyl]carbonyl]glycine as prolyl hydroxylase 2 (PHD2) inhibitor. And the patent contained the following:

Oral solid pharmaceutical compositions contain N-[[1-[[6-(4-chlorophenoxy)-3-pyridinyl]methyl]-4-hydroxy-2-oxo-1,2,5,6-tetrahydro-3-pyridinyl]carbonyl]glycine or its pharmaceutically acceptable salt as active ingredient. The compound inhibits PHD2, thus useful for prevention and treatment of anemia. The experimental process involved the reaction of tert-Butyl 4-amino-4-(2-methoxy-2-oxoethyl)piperidine-1-carboxylate(cas: 362703-57-9).Synthetic Route of 362703-57-9

The Article related to tetrahydropyridinylcarbonylglycine preparation antianemic prolyl hydroxylase inhibitor oral solid, Pharmacology: Effects Of Cardiovascular, Hematologic, and Renal Drugs and other aspects.Synthetic Route of 362703-57-9

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem